31
Participants
Start Date
January 28, 2014
Primary Completion Date
January 29, 2015
Study Completion Date
April 2, 2015
BAY1067197 (10 mg)
10 mg BAY1067197 for 7 d treatment once daily as oral application
BAY1067197
The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.
Placebo (10 mg)
10 mg Placebo for 7 d treatment once daily as oral application
Placebo
5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
Berlin
Milan
Bergamo
Brescia
Groningen
Wroclaw
Lead Sponsor
Bayer
INDUSTRY